TrovaGene (TROV) Shares Gap Up to $0.25

TrovaGene Inc (NASDAQ:TROV) gapped up prior to trading on Monday . The stock had previously closed at $0.24, but opened at $0.25. TrovaGene shares last traded at $0.26, with a volume of 2656609 shares changing hands.

TROV has been the topic of a number of research reports. Maxim Group set a $4.00 price objective on TrovaGene and gave the company a “buy” rating in a research note on Wednesday, October 18th. cut TrovaGene from a “buy” rating to a “hold” rating in a research note on Wednesday, November 15th.

TrovaGene (NASDAQ:TROV) last announced its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%. The business had revenue of $0.12 million for the quarter.

Several institutional investors and hedge funds have recently made changes to their positions in the company. LMR Partners LLP purchased a new stake in TrovaGene in the second quarter worth approximately $151,000. Susquehanna International Group LLP raised its position in shares of TrovaGene by 2,781.0% in the 2nd quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock worth $174,000 after acquiring an additional 133,240 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of TrovaGene by 1,079.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock worth $351,000 after acquiring an additional 254,601 shares in the last quarter. Hedge funds and other institutional investors own 13.73% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at

TrovaGene Company Profile

Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply